A study published in Blood found that tandem chimeric antigen receptor (CAR) T-cells showed dual antigen targeting of CD19 and CD20 and elicited a potent and durable anti-tumor response in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
Researchers designed a series of tandem CARs and found that tandem CAR7 T-cells showed dual antigen targeting of CD19 and CD20, as well as formed superior and stable immunological synapse structures, which may be related to their robust anti-tumor activity, according to the researchers.
The open-label, single-arm, phase I/IIa trial enrolled 33 patients with relapsed/refractory NHL, and 28 patients received CAR infusion after conditioning chemotherapy.
The primary objective was safety and tolerability of the tandem CAR7 T-cells, while efficacy and progression-free survival (PFS) were evaluated as secondary objectives. Half of patients (n=14) experienced cytokine release syndrome, 36% of which were grade 1/2 and 14% were grade 3. No cases of grade ≥3 CAR T-cell-related encephalopathy syndrome (CRES) were reported. One patient died from a treatment-related severe pulmonary infection.
The overall response rate was 79% (95% confidence interval [CI], 60-92), and the complete response rate was 71%. PFS at 12 months was 64% (95% CI, 43-79).
“Tandem CAR7 T-cells elicited a potent and durable anti-tumor response, but not grade ≥3 CRES, in patients with relapsed/refractory NHL,” the researchers concluded.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.